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2014, accepted Fetrial ﬁbrillation (AF) is the most common sustained arrhythmia in clinical practice. AF and its complications
are responsible for important population morbidity and mortality. Presently available therapeutic approaches
have limited efﬁcacy and nontrivial potential to cause adverse effects. Thus, new mechanistic knowledge
is essential for therapeutic innovation. Atrial arrhythmogenic remodeling, deﬁned as any change in atrial
structure or function that promotes atrial arrhythmias, is central to AF. Remodeling can be due to underlying
cardiac conditions, systemic processes and conditions such as aging, or AF itself. Recent work has underlined
the importance of remodeling in AF, provided new insights into basic mechanisms, and identiﬁed new
biomarker/imaging approaches to follow remodeling processes. The importance of intracellular Ca2þ handling
abnormalities has been highlighted, both for the induction of triggered ectopic activity and for the activation
of Ca2þ-related cell signaling that mediates proﬁbrillatory remodeling. The importance of microRNAs, which
are a new class of small noncoding sequences that regulate gene expression, has emerged in both electrical
and structural remodeling. Remodeling related to aging, cardiac disease, and AF itself is believed to underlie
the progressive nature of the arrhythmia, which contributes to the complexities of long-term management.
New tools that are being developed to quantify remodeling processes and monitor their progression
include novel biomarkers, imaging modalities to quantify/localize ﬁbrosis, and noninvasive monitoring/
mapping to better characterize the burden of AF and identify arrhythmic sources. This report reviews
recent advances in the understanding of the basic pathophysiology of atrial remodeling and potential
therapeutic implications. (J Am Coll Cardiol 2014;63:2335–45) ª 2014 by the American College of
Cardiology FoundationAtrial ﬁbrillation (AF) is a major cause of cardiovascular
morbidity and mortality (1). AF is a ﬁnal common endpoint
of atrial remodeling caused by a variety of cardiac diseases
and conditions (2) and itself causes important remode-
ling that contributes to the progressive nature of the
arrhythmia. A detailed review of the subject was published
in 2008 (3). Since then, an enormous amount has been
learned about atrial remodeling, its mechanisms, and its
role in the AF disease process. Here, we will focus on
progress since that report (over the past 6 years), particu-
larly in terms of understanding the basic mechanisms and
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bruary 17, 2014.Overview of AF Pathophysiology and
Contribution of Remodeling
There are 4 principal pathophysiological mechanisms
contributing to AF (1–4): electrical remodeling, structural
remodeling, autonomic nervous system changes, and Ca2þ
handling abnormalities (red boxes in Fig. 1). Each of
these can result from cardiac disease conditions (blue
boxes in Fig. 1) and promote the development of AF; AF
in turn causes AF-promoting abnormalities in each of
these areas (red dashed arrows in Fig. 1). AF-induced
atrial remodeling enhances the vulnerability of the heart
to AF induction and maintenance; this auto-reinforcing
property of AF is often referred to by the term “AF be-
gets AF.” Focal ectopic ﬁring (yellow boxes in Fig. 1) can
maintain AF or trigger re-entrant AF through a re-entry-
maintaining substrate (green boxes in Fig. 1) that has
the appropriate conditions to allow re-entry to be induced
and then sustained. Induction and maintenance of re-entry
require a critical balance between refractory and conduc-
tion properties, as discussed in detail by Wakili et al. (2)
and Nattel et al. (3). AF is by deﬁnition a highly irreg-
ular atrial rhythm, yet paradoxically it can be maintained
by regularly ﬁring sources (sometimes called “drivers”),
whether rapidly ﬁring ectopic foci or single rapidly rotating
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2336re-entry circuits, by virtue of
spatially heterogeneous “ﬁbrilla-
tory conduction” (5). The ways
in which the 4 principal mech-
anisms (electrical remodeling,
structural remodeling, auto-
nomic nervous system changes,
and Ca2þ handling abnormal-
ities) occur and promote AF
are detailed in the following
text.
Electrical Remodeling
Atrial electrophysiological prop-
erties are governed by ion chan-
nels, pumps, and exchangers, any
of which can be altered by atrial
remodeling. The principal com-
ponents of electrical remodeling
identiﬁed to date include decreased
L-type Ca2þ current (ICaL, car-
ried by L-type Ca2þ channels
[LTCCs]), rectiﬁer background
Kþ current (IK1) and constitutive
acetylcholine-regulated Kþ cur-
rent (IKACh), and abnormal
expression/distribution of the
gap junction connexin hemi-
channels that connect cardio-
myocytes electrically. Electrical
remodeling creates a re-entry-
prone substrate.
Down-regulation of ICaL. Ca
2þ
handling in atrial cardiomyo-
cytes is shown schematically in
Figure 2. For more details, see
reviews by Wakili et al. (2) and
Nattel and Dobrev (4). Ca2þ
enters through LTCCs during
AP depolarization, triggering
a secondary release of large
amounts of Ca2þ from the sar-
coplasmic reticulum (SR) Ca2þ
stores via SR Ca2þ release
channels called ryanodine receptors (RyR2s). This Ca2þ-
induced Ca2þ release induces myoﬁlament movement/cell
contraction. SR Ca2þ stores are governed by the balance
between Ca2þ release from the SR into the cytosol via RyR2
channels and Ca2þ uptake into the SR via the SR Ca2þ–
adenosine triphosphatase (SERCA2a). Under basal con-
ditions, SERCA2a function is limited by the inhibitory
subunit phospholamban (PLB). Most Ca2þ in the SR is
bound to the buffer calsequestrin. In situations of adrenergic
stimulation or cellular Ca2þ loading, Ca2þ/calmodulin ki-
nase type 2 (CaMKII) and protein kinase A becomeactivated, phosphorylating RyR2s (increasing their open
probability) and PLB (causing it to dissociate from and
disinhibit SERCA2a). While this system is adaptive under
conditions of acute stress-related increases in demand for
cardiac work, sustained Ca2þ loading and CaMKII activa-
tion cause abnormal diastolic RyR2 Ca2þ releases. The
released Ca2þ is handled via transmembrane extrusion
through the Naþ/Ca2þ exchanger (NCX), which carries
an inward current that causes phase 4 membrane de-
polarizations known as delayed afterdepolarizations
(DADs).
During AF, the high atrial rate causes accumulation of
intracellular Ca2þ, engaging homeostatic defense mecha-
nisms against chronic Ca2þ overload. The Ca2þ-dependent
calcineurin/nuclear factor of activated T cells (NFAT) sys-
tem is then activated. NFAT translocates into the nucleus
and suppresses transcription of the gene encoding Cav1.2
LTCCs (CACNA1C), decreasing ICaL (Fig. 3) (2,6).
Reduced ICaL decreases the inward Ca
2þ current, main-
taining the AP plateau, shortening the AP duration (APD),
and thereby promoting re-entry.
Up-regulation of IK1. IK1, the principal background car-
diac inward rectiﬁer current, determines the resting po-
tential and terminal phase 3 repolarization and is composed
primarily of Kir2.1 subunits. Inward rectiﬁer currents such
as IK1 are a particularly important determinant of AF-
maintaining re-entry (7); IK1 is up-regulated in AF (2).
Another important inward-rectiﬁer current, IKACh, medi-
ates the effects of acetylcholine and underlies the marked
ability of vagal activation to promote AF by causing
spatially heterogeneous increases in inward rectiﬁer current
and reductions in APD (8). AF suppresses agonist-induced
IKACh but enhances a constitutive form (IKAChc), promot-
ing maintenance of AF (9,10). Activation of IKAChc is
induced by altered protein kinase C regulation of IKACh
function resulting from AF-induced atrial tachycardia and
Ca2þ loading (10).
Up-regulation of the small conductance Ca2D-activated
KD channel. Small conductance Ca2þ-activated Kþ
channels, encoded by the genes KCNN1/KCNN2/KCNN3,
are activated by increased levels of intracellular Ca2þ. Single
nucleotide polymorphisms of KCNN3 are associated with
the prevalence of AF (11). Recent work suggests that rapid
atrial activation, as seen in AF, may up-regulate small
conductance Ca2þ-activated Kþ channel expression, which
contributes to AF maintenance and susceptibility by
abbreviating APD (12). In addition, noncardiomyocyte
small conductance Ca2þ-activated Kþ channels could play
a role in promotion of AF, for example, in ﬁbroblasts (via
ﬁbrosis), smooth muscle cells (cardiac vascular changes
and/or hypertension), or neurons (altered autonomic
regulation).
Gap junction remodeling. Gap junction ion channels
such as connexin 40 and connexin 43 mediate
cardiomyocyte-to-cardiomyocyte electrical coupling. Con-
nexin 43, which is encoded by GJA1, is expressed in all
Figure 1 Major Components of Atrial Remodeling Underlying the Pathophysiology of AF
The principal AF-promoting mechanisms resulting from AF-inducing remodeling are shown in red boxes. Focal ectopic ﬁring is usually due to DADs that reach threshold and cause
spontaneous AP generation. A susceptible reentry substrate requires abbreviated refractoriness (which depends primarily on APD) and/or conduction abnormalities. These
mechanisms can be the result of AF-promoting cardiac diseases but can also result from the consequences of AF itself. AF ¼ atrial ﬁbrillation; APD ¼ action potential duration;
DADs ¼ delayed afterdepolarizations; IKACh ¼ acetylcholine-regulated Kþ current.
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2337working cardiac tissue; connexin 40, which is encoded by
GJA5, is expressed mainly in atria and the conduction
system (13). Alterations in gap junction function contribute
signiﬁcantly to AF-induced remodeling (14). Missense
somatic mutations in GJA5 underlie cases of idiopathic AF
(15), and GJA5 promoter sequence variants are associated
with AF vulnerability (16).Structural Remodeling
Structural remodeling is characterized by atrial enlargement
and tissue ﬁbrosis. Under some functional conditions, atrial
dimension is a key determinant of the persistence of AF-
maintaining reentry (17). Fibrosis promotes AF by inter-
rupting ﬁber bundle continuity and causing local conduction
disturbances (18). In addition, ﬁbroblast-cardiomyocyte
interactions may cause arrhythmogenic changes in car-
diomyocyte bioelectricity (19). Atrial ﬁbrosis appears to be
a common endpoint of a wide range of AF-promoting
conditions and may predict recurrences (20). Further-
more, AF appears to promote atrial ﬁbrosis (21), which
contributes importantly to therapeutic resistance in pa-
tients with long-standing arrhythmia (22).Autonomic Nervous System Changes
Autonomic nervous system control regulates atrial bio-
electricity and contributes to the initiation and mainte-
nance of AF. Adrenergic activation increases ICaL, RyR2
open probability, and SR Ca2þ load (Fig. 2) via phosphory-
lation by CaMKII and protein kinase A. The risk of DADs is
consequently enhanced, and adrenergic activation may play a
critical role in AF due to formation of ectopic activity in the
context of various remodeling-induced paradigms (23,24).
Autonomic hyperinnervation is a consequence of AF-related
remodeling and contributes to the vulnerable AF substrate (25).Ca2D Handling Abnormalities
The most signiﬁcant direct atrial proﬁbrillatory consequence
of Ca2þ handling abnormalities is the induction of DAD-
related spontaneous atrial ectopic activity. Patients with
long-standing persistent AF have an increased risk of
arrhythmogenic DADs/triggered activity (26). They show
enhanced CaMKII activity, with associated hyperpho-
sphorylation and increased open probability of RyR2,
causing increased CaMKII-dependent SR Ca2þ leak (26).
Figure 2 Cellular Ca2þ Handling and Mechanisms Underlying DADs
Key structures governing Ca2þ handling include the LTCC, through which Ca2þ enters the cell; cardiac SR, which is the principal subcellular Ca2þ storage organelle; RyR2,
through which Ca2þ leaves the SR to produce Ca2þ-induced Ca2þ release; SERCA2a, the principal SR Ca2þ uptake mechanism that maintains SR Ca2þ load; and NCX, which
removes Ca2þ from the cytosol by exchanging it for extracellular Naþ across the cell membrane. Ca2þ-induced Ca2þ release during systole causes cardiomyocyte contraction.
The Ca2þ released during systole is removed from the cytosol during diastole by SERCA2a and NCX, allowing cell relaxation. Diastolic Ca2þ release from the SR is abnormal and
transpires with disturbed RyR2 function and/or SR Ca2þ overload; when it occurs, the released Ca2þ is handled by NCX, producing an inward NCX current that causes a DAD.
For more detailed discussion, see the text. CaMKII ¼ Ca2þ/calmodulin-dependent protein kinase II; CSQ ¼ calsequestrin; LTCC ¼ L-type Ca2þ channel; MLC-2a ¼ myosin light
chain 2a; MyBP-C ¼ myosin binding protein C; NCX ¼ Naþ/Ca2þ exchanger; P ¼ phosphate; PKA ¼ protein kinase A; PLB ¼ phospholamban; PP1 ¼ protein phosphatase 1;
PP2A ¼ protein phosphatase 2A; RyR2 ¼ ryanodine receptor type 2; SERCA2a¼ sarcoplasmic reticulum Ca2þ–adenosine triphosphatase; SLN ¼ sarcolipin; SR ¼ sarcoplasmic
reticulum; Tn-I ¼ troponin I; Tn-C ¼ troponin C; other abbreviations as in Figure 1.
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2338In addition, NCX is up-regulated, increasing the size of
DAD-generating inward currents for any given amount of
aberrant Ca2þ release. These abnormalities appear to be
caused by AF-induced remodeling, with CaMKII activa-
tion resulting from Ca2þ loading due to sustained very
rapid atrial activation. While long-standing persistent AF
is likely maintained by complex multiple circuit reentry
(2–5,27), ectopic activity may contribute by reinitiating
AF should it terminate spontaneously or via medical
intervention. Recent work points to a pre-disposition to
DADs in patients with paroxysmal AF that likely plays
a more primary role in arrhythmogenesis (28). The prin-
cipal underlying mechanisms include increased SR Ca2þ
load due to PLB hyperphosphorylation and RyR2abnormalities, including increased expression and enhanced
open probability without RyR2 hyperphosphorylation (28).
These abnormalities may be due to underlying heart disease
or genetic pre-disposition but are not secondary to AF
because patients who provided atrial tissue samples had
been in sinus rhythm for a median of 10 to 20 days before
surgery.
Signaling Systems Involved in Atrial Remodeling
In the past few years, there have been substantial advances
in understanding the signaling systems that cause atrial
remodeling. Such work is important if more effective pre-
ventive measures are to be developed.
Figure 3 Ca2þ-Related Cell Signaling and Atrial Remodeling in AF
Remodeling in a cardiomyocyte is represented at the top and a ﬁbroblast at the bottom. AF engages Ca2þ-dependent signaling via increased rate and reactive oxygen
species (ROS) generation in cardiomyocytes, cell stretch in ﬁbroblasts, and receptor-activating molecules (AT-II and TGF-b) in both. AT-II ¼ angiotensin II; AT-IIR ¼ angiotensin II
receptor; CaM ¼ calmodulin; Cn ¼ calcineurin; DAG ¼ diacylglycerol; ECM ¼ extracellular matrix; ER ¼ endoplasmic reticulum; ERK 1/2 ¼ extracellular signal–regulating kinase
1/2; IP3 ¼ inositol triphosphate; IP3R ¼ inositol triphosphate receptor; MAPK ¼ mitogen-activated protein kinase; miR ¼ microRNA; NFAT ¼ nuclear factor of activated T cells;
PKC ¼ protein kinase C; PLC ¼ phospholipase C; SAC ¼ stretch activated channel; aSMA ¼ a–smooth muscle actin; TGFb ¼ transforming growth factor-b; TGFbR ¼ trans-
forming growth factor b receptor; TRPM7 ¼ TRP melastatin-related 7; other abbreviations as in Figures 1 and 2.
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2339Ca2D signaling and electrical remodeling. Recent work
has indicated a central role for Ca2þ signaling in atrial
remodeling (4). Figure 3 shows the molecular pathways that
induce AF-related remodeling in cardiomyocytes and ﬁ-
broblasts, highlighting the role of intracellular Ca2þ. In
addition to down-regulating the transcription of Cav1.2
subunits and down-regulating ICaL, NFAT nuclear trans-
location resulting from AF also down-regulates the pro-
duction of a microRNA, miR-26 (29). Mir-26 targets
KCNJ2, the gene that encodes Kir2.1 subunits, and down-
regulation of miR-26 causes up-regulation of IK1 that
strongly promotes persistence of AF (29).
CaMKII is activated in AF because of the persistent Ca2þ
load resulting from high atrial rates as well as AF-induced
reactive oxygen species formation (30). CaMKII regulatesthe activities of key Ca2þ-handling proteins such as LTCC,
RyR2, and PLB (Fig. 2) (4), promoting DADs/triggered
activity. CaMKII phosphorylation also activates down-
stream effectors of remodeling such as class II histone
deacetylase, which plays an important role in atrial remodeling
(31), and nuclear factor kB, which modulates proin-
ﬂammatory genes associated with AF (32). Angiotensin II
(AT-II) and other proﬁbrotic mediators can enhance pro-
duction of diacylglycerol, which activates protein kinase C.
Conventional protein kinase C is stimulated by an increase in
levels of intracellular Ca2þ and induces downstream signaling
cascades such as mitogen-activated protein kinases and nuclear
factor kB, controlling diverse cell functions such as ﬁbroblast
activation, cardiomyocyte hypertrophy, and inﬂammation
(Fig. 3) (33), which can affect global atrial electrical function.
Figure 4 Biogenesis and Actions of miRNA
Schematic representation of microRNA (miRNA) biogenesis and action. miRNAs produce their effects via single-stranded short nucleotide sequences (“seed strands”) that bind
with high afﬁnity via “seed sequences” to complementary sequences on the noncoding portion of messenger RNAs (mRNAs). This binding interferes with ribosomal translation of
protein from the target mRNA, reducing its protein expression. In addition, under conditions of very high complementarity, the target mRNA is destabilized, reducing mRNA
expression. RISC ¼ RNA-induced silencing complex; TF ¼ transcription factor.
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2340Ca2D signaling and structural remodeling. Fibroblasts are
key players in cardiac structural remodeling (19). Key
ﬁbroblast Ca2þ handling processes and their role in atrial
remodeling are represented in Figure 3. Nonexcitable cells
such as ﬁbroblasts lack voltage-gated Ca2þ channels.
Instead, they possess 2 primary mechanisms of intracellular
Ca2þ regulation, inositol triphosphate (IP3)-mediated Ca2þ
release from the endoplasmic reticulum (ER) (Ca2þ storage
organelle in nonexcitable cells, analogous to the SR in car-
diomyocytes) and Ca2þ entry via voltage-independent
Ca2þ-permeable sarcolemmal channels such as stretch-
activated channels, receptor-operated channels, and Ca2þ
store depletion-operated channels (19,32). Stretch-activated
channels, receptor-operated channels, and Ca2þ store
depletion-operated channels are functional classiﬁcations;
the details of channel structure and their role still remain
unclear.Proﬁbrotic mediators modulate ER Ca2þ release and
Ca2þ entry into ﬁbroblasts. For example, receptor binding of
AT-II activates phospholipase C, cleaving phosphatidyli-
nositol-4,5-bisphosphate into diacylglycerol and IP3. IP3
diffuses to the ER and binds to IP3 receptors, inducing ER
Ca2þ release. Diacylglycerol can directly activate speciﬁc
Ca2þ-permeable transient receptor-potential TRP channels
(TRPC3/6/7), causing Ca2þ entry (32). Increased cytosolic
Ca2þ levels (whether because of increased Ca2þ entry across
the cell membrane or increased release from the ER) cause
ﬁbroblast proliferation and differentiation into myoﬁbro-
blasts, promoting ﬁbrosis (34).
TRP channels are important Ca2þ entry pathways in
ﬁbroblasts. TRP melastatin-related 7 (TRPM7) channels
are up-regulated in ﬁbroblasts isolated from the right atrial
tissues of patients with long-standing persistent AF com-
pared with sinus rhythm controls (35). In vitro TRPM7
Figure 5 miRNAs and Atrial Remodeling in AF
Schematic representation of established miRNA signaling consequences in cardiomyocytes (top) and ﬁbroblasts (bottom). miRNAs act by down-regulating the expression
of target genes. Thus, miRNA down-regulation increases the expression of the target gene, whereas miRNA up-regulation suppresses the target gene. Cn/NFAT ¼ calcineurin/
nuclear factor of activated T cells; CV ¼ conduction velocity; other abbreviations as in Figures 1 to 3.
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2341knockdown decreases ﬁbroblast Ca2þ entry and prevents
ﬁbroblast differentiation caused by transforming growth
factor (TGF)-b (35). TGF-b is produced by both ﬁbro-
blasts and cardiomyocytes and is a key mediator of atrial
ﬁbrosis induced by a wide range of stimuli, including AT-II
(36). AT-II stimulation increases TGF-b gene/protein
synthesis in both cardiomyocytes and ﬁbroblasts. Auto-
crine and paracrine TGF-b/AT-II networks act to amplify
proﬁbrotic reactions (Fig. 3) (36,37). TGF-b activates
Smad2/3 signaling to potentiate ﬁbroblast activation
(36,37). Rapid pacing of atrial cardiomyocytes induces
paracrine AT-II signaling, which causes adjacent atrial
ﬁbroblasts to secrete TGF-b, likely contributing to ﬁbrosis
due to long-standing AF (38). Thus, the ability of TRPM7
knockdown to suppress TGF-b signaling points to a central
role of ﬁbroblast Ca2þ in mediating proﬁbrotic responses.
Atrial TRP canonical 3 (TRPC3) channels also mediateﬁbroblast Ca2þ entry; TRPC3-mediated Ca2þ entry en-
hances phosphorylation of extracellular signal–regulated
kinase (ERK), activating ﬁbroblasts (34). TRPC3 expres-
sion is up-regulated in patients with long-standing persis-
tent AF and animal models of AF (34). Inhibition of
TRPC3 suppresses ﬁbroblast proliferation and myoﬁbro-
blast differentiation in vitro, and in vivo TRPC3 blockade
in dogs with 1-week electrically maintained AF prevents
AF-induced ﬁbroblast activation and suppresses AF pro-
motion (34).
Recent evidence points to a key role of cell Ca2þ in atrial
structural remodeling. Mice overexpressing a repressor
variant of the cyclic adenosine monophosphate response
element modulator (CREM) develop age-dependent
atrial arrhythmias, presenting atrial ectopy at a young age
(3 months) followed by spontaneous-onset AF (39).
CREM-transgenic (TG) mice manifest atrial dilation,
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2342ﬁbrosis, and conduction slowing, along with increased SR
Ca2þ leak (40). The Ca2þ leak appears to be caused by
CaMKII hyperphosphorylation of RyR2, because inhibi-
tion of CaMKII hyperphosphorylation by organic
blockers or by genetic block with a nonphosphorylatable
RyR2 mutation suppresses Ca2þ leak (40). Long-term
prevention of RyR2 Ca2þ leak by crossing CREM-TG
mice with RyR2-S2814A-TG (CaMKII nonphospho-
rylatable) mice delays atrial ectopy, prevents atrial struc-
tural remodeling, and eliminates spontaneous development
of AF (40). These results suggests that accumulation of
intracellular Ca2þ may cause not only DADs/triggered ac-
tivity but also long-term atrial structural remodeling. These
observations may provide novel insights into mechanisms
underlying the pattern of AF progression seen in many
patients.
MicroRNAs and AF
A rapidly emerging area in the pathophysiology of AF is the
role of microRNAs (miRNAs or miRs), which are small
noncoding RNAs (w22 nucleotides) that negatively regulate
target genes. Cardiac miRNA expression proﬁles change in
response to pathological conditions and are believed to play a
pathophysiological role in many.
Fundamentals of miRNAs. Figure 4 summarizes the fac-
tors governing the production and effects of miRNAs. RNA
polymerase II mediates transcription of primary miRNAs
(100 to 1,000 base pairs) under the control of standard
transcription factors. Primary miRNAs are cleaved by the
enzyme Drosha into precursor miRNAs (w70 nucleotides
with short stem-loop structure), which are exported into the
cytoplasm by Exportin 5. Dicer trims the stem loops from
precursor miRNAs, producing double-stranded mature
miRNA duplexes. The miRNA duplex then dissociates into
a “passenger” strand and a “seed” strand, which is incorpo-
rated into the RNA-induced silencing complex. The
miRNA/RNA-induced silencing complex binds to the 30
untranslated region of target messenger RNAs (mRNAs)
and blocks ribosomal processing/translation of the target
protein (reducing protein expression, the principal miRNA
effect). When complementarity between the miRNA seed
region and the target mRNA is particularly high, mRNA
stability is reduced (also reducing mRNA expression).
miRNAs involved in atrial remodeling. miRNAs con-
tribute to a wide range of atrial remodeling processes
(Fig. 5). Evidence for the participation of speciﬁc miRNAs
is presented in the following text.
miR-1. miR-1 is abundantly expressed in cardiomyocytes
(but not ﬁbroblasts). In myocardial infarction, miR-1 is up-
regulated, suppressing the expression of KCNJ2 (encoding
IK1) and GJA1 (encoding connexin 43) (41). There is evi-
dence that down-regulation of miR-1 may contribute to
up-regulation of IK1 in AF (42). MiR-1 targets protein
phosphatases, and up-regulation of miR-1 in heart failure
(HF) may underlie Ca2þ-dependent arrhythmic activity (43).miR-21. miR-21 targets Sprouty 1, a negative regulator of
ﬁbroblast ERK signaling (44). Rats with post–myocardial
infarction HF show AF-promoting ﬁbrotic remodeling
with up-regulation of miR-21, decreased expression of
Sprouty 1, and increased ERK phosphorylation; miR-21
knockdown suppresses left atrial ﬁbrosis and promotion
of AF (45). Up-regulation of MiR-21 and down-regulation
of Sprouty 1 are seen in left atrial tissues from patients with
AF, miR-21 is up-regulated in murine AF models, and
miR-21 knockdown suppresses atrial ﬁbrosis in mice with
myocardial infarction (46).
miR-26. miR-26 targets the KCNJ2 gene encoding Kir2.1
(IK1). miR-26 knockdown causes up-regulation of IK1 and
promotion of AF in mice (29). The host gene encoding
miR-26 has multiple NFAT binding sites. MiR-26
expression decreases in patients with AF and canine AF
models; therefore, NFAT-dependent down-regulation of
miR-26 likely underlies up-regulation of IK1 in AF (29).
There is also evidence that MiR-26 contributes to atrial
structural remodeling. As detailed in the preceding text, AF-
associated TRPC3 up-regulation is an important ﬁbroblast
activator. miR-26 targets the gene encoding TRPC3 chan-
nels, and miR-26 knockdown increases TRPC3 expression
in canine atrial ﬁbroblasts, mimicking the effects of AF (34).
NFAT nuclear translocation is observed in left atrial ﬁbro-
blasts of dogs with AF. Pharmacological blockade of
NFAT in canine atrial ﬁbroblasts increases miR-26 ex-
pression and decreases levels of TRPC3 protein, conﬁrm-
ing NFAT/miR-26 regulation of TRPC3 (34).
miR-29. TGF-b negatively regulates miR-29 expression,
and miR-29 targets extracellular matrix (ECM) genes such
as collagen 1 and ﬁbrillin 1 (47). Expression of miR-29
decreases in the left atria of dogs with HF, which develop an
AF-maintaining ﬁbrotic substrate, whereas expression of
miR-29–targeted ECM genes (collagen 1 and collagen 3)
increases (48). miR-29 knockdown in mice, to mimic the
HF-induced decrease in miR-29, increases atrial collagen
production. Furthermore, both plasma and atrial tissue miR-
29 levels decrease in patients with AF, suggesting potential
value as a biomarker (48).
miR-133 and miR-590. TGF-b and TGF-b receptor are
targets of miR-133 and miR-590 (49). Prolonged admin-
istration of nicotine to dogs, mimicking sustained tobacco
smoking, induces atrial proﬁbrillatory ﬁbrotic remodeling
(49). Nicotine decreases miR-133 and miR-590 expression
in atrial ﬁbroblasts and up-regulates TGF-b and TGF-b
receptor, increasing collagen production (49). miR-133 also
targets collagen 1, and its down-regulation directly increases
ECM production in cardiac ﬁbroblasts (50).
miR-328. miR-328 targets the genes encoding LTCC
subunit genes CACNA1C (encoding LTCC a subunits) and
CACNB1 (encoding b1 subunits) (51). Atrial miR-328 is
up-regulated in dogs with AF. Cardiac-speciﬁc miR-328–
overexpressing mice are vulnerable to AF, and miR-328
knockdown restores Cav1.2 and Cavb1 expression and re-
duces AF vulnerability (51).
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2343Translational Implications
Since the ﬁrst description of the role of ﬁbrotic structural
remodeling in AF 15 years ago (52), there has been in-
creasing recognition of the importance of atrial ﬁbrosis in
the pathophysiology of AF. Modern imaging methods have
been developed to detect, localize, and quantify atrial ﬁbrosis
(53), which has been found to be correlated with outcomes
such as stroke (54) and recurrence of AF. Biomarkers are
becoming increasingly valuable in monitoring cardiac disease
activity and therapeutic responses, with a variety of inter-
esting candidates in AF (55). ECM-related proteins are
measurable in the blood, and their plasma concentrations
have been found to correlate with the risk of AF, suggesting
potential value as biomarkers (55–57). Imaging approaches
are being combined with highly sophisticated mathematical
models of cardiac bioelectricity to gain insights into mech-
anisms by which ﬁbrosis promotes AF in humans, with the
hope of eventual individual-patient, mechanism-based
therapeutics (58). In vivo activation mapping methods may
allow targeted therapy of AF-speciﬁc mechanisms (59,60)
and may eventually permit relationships to be established
between atrial substrates and mechanisms initiating and/or
maintaining AF.
Recognition of the role and mechanisms of remodeling in
AF led to the notion of targeting underlying substrates to
provide more speciﬁc approaches (61). Although this
attractive goal is still far from unrealized, great progress has
been made. “Upstream therapy” is a term that describes the
targeting of remodeling-induced substrate development.
Recent detailed reviews indicate that some efforts at up-
stream therapy have shown promise but that clear clinical
indications remain to be conﬁrmed and deﬁned (62,63). To
provide effective preventive therapy, it will be necessary to
identify at-risk patients early enough to prevent the devel-
opment of AF substrates before they become ﬁxed and
irreversible and to have available safe and effective thera-
peutic interventions (64). An improved understanding of key
molecular pathways leading to AF substrates should help in
deﬁning targets for therapeutic intervention.
Besides targeting pathways leading to remodeling, better
appreciation of the resulting arrhythmogenic mechanisms
may also help in improving therapeutic targeting. Our in-
creasing recognition of the importance of Ca2þ mishan-
dling in AF has led to the development of interventions
targeting speciﬁc Ca2þ handling components such as
CaMKII and RyR2 leak (4). Molecular therapeutics with
cell- and gene-based therapies are becoming conceivable,
and proof of principle has been achieved with connexin
gene transfer in a pig model of electrical pacing–induced
AF (14,65) and miR-21 knockdown in a rat model
of ﬁbrosis-related AF post–myocardial infarction (42).
Autonomic remodeling has been targeted by low-level vagal
nerve stimulation in a canine model of paroxysmal AF (66),
and autonomic ganglion ablation shows some clinical
promise (67).Recognition of the importance of atrial remodeling has
led to the notion of intervening early and aggressively in
patients with AF in an attempt to forestall remodeling and
attendant complications (68). The ultimate goal is to provide
safe and effective, ideally personalized, therapies for AF.
Although we are certainly not yet at the threshold of
achieving this goal, advances in knowledge, technologies,
and analytical approaches make effective personalized ther-
apy a realistic goal for the near future (69).Acknowledgment
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